Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.

British journal of pharmacology

Miyake T, Tsutsui H, Haraya K, Tachibana T, Morimoto K, Takehara S, Ayabe M, Kobayashi K, Kazuki Y.
PMID: 34232502
Br J Pharmacol. 2021 Nov;178(21):4335-4351. doi: 10.1111/bph.15612. Epub 2021 Sep 06.

BACKGROUND AND PURPOSE: P-glycoprotein (P-gp) exhibits a broad substrate specificity and affects pharmacokinetics, especially intestinal absorption. However, prediction, in vivo, of P-gp-mediated drug-drug interaction (DDI) and non-linear absorption at the preclinical stage, is challenging. Here we evaluate the use...

Cite
Miyake T, Tsutsui H, Haraya K, et al. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. Br J Pharmacol. 2021;178(21):4335-4351doi: 10.1111/bph.15612.
Miyake, T., Tsutsui, H., Haraya, K., Tachibana, T., Morimoto, K., Takehara, S., Ayabe, M., Kobayashi, K., & Kazuki, Y. (2021). Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. British journal of pharmacology, 178(21), 4335-4351. https://doi.org/10.1111/bph.15612
Miyake, Taiji, et al. "Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice." British journal of pharmacology vol. 178,21 (2021): 4335-4351. doi: https://doi.org/10.1111/bph.15612
Miyake T, Tsutsui H, Haraya K, Tachibana T, Morimoto K, Takehara S, Ayabe M, Kobayashi K, Kazuki Y. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. Br J Pharmacol. 2021 Nov;178(21):4335-4351. doi: 10.1111/bph.15612. Epub 2021 Sep 06. PMID: 34232502.
Copy Download .nbib Format: NLM
New Insight into Effects of β-Blockers on Arterial Functions.

Pulse (Basel, Switzerland)

Eguchi K.
PMID: 27195240
Pulse (Basel). 2016 Apr;3(3):190-4. doi: 10.1159/000443615. Epub 2016 Jan 20.

The effects of β-blockers on arterial properties are not well investigated. In our recent study, we compared the effects of the two β-blockers celiprolol and bisoprolol on blood pressure, baroreflex sensitivity (BRS), flow-mediated vasodilatation, and vascular stiffness. We found...

Cite
Eguchi K. New Insight into Effects of β-Blockers on Arterial Functions. Pulse (Basel). 2016;3(3):190-4doi: 10.1159/000443615.
Eguchi, K. (2016). New Insight into Effects of β-Blockers on Arterial Functions. Pulse (Basel, Switzerland), 3(3), 190-4. https://doi.org/10.1159/000443615
Eguchi, Kazuo. "New Insight into Effects of β-Blockers on Arterial Functions." Pulse (Basel, Switzerland) vol. 3,3 (2016): 190-4. doi: https://doi.org/10.1159/000443615
Eguchi K. New Insight into Effects of β-Blockers on Arterial Functions. Pulse (Basel). 2016 Apr;3(3):190-4. doi: 10.1159/000443615. Epub 2016 Jan 20. PMID: 27195240; PMCID: PMC4865072.
Copy Download .nbib Format: NLM
Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches.

Cardiology in review

Assavarittirong C, Au TY, Nguyen PV, Mostowska A.
PMID: 34560710
Cardiol Rev. 2021 Sep 15; doi: 10.1097/CRD.0000000000000419. Epub 2021 Sep 15.

Vascular Ehlers-Danlos syndrome (vEDS) is a rare autosomal dominant genetic disorder. It is the most fatal among all types of EDS. In addition to typical EDS characteristics, vEDS patients are at risk of blood vessel rupture due to possession...

Cite
Assavarittirong C, Au TY, Nguyen PV, et al. Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches. Cardiol Rev. 2021;doi: 10.1097/CRD.0000000000000419.
Assavarittirong, C., Au, T. Y., Nguyen, P. V., & Mostowska, A. (2021). Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches. Cardiology in review, . https://doi.org/10.1097/CRD.0000000000000419
Assavarittirong, Chanika, et al. "Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches." Cardiology in review vol. (2021). doi: https://doi.org/10.1097/CRD.0000000000000419
Assavarittirong C, Au TY, Nguyen PV, Mostowska A. Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches. Cardiol Rev. 2021 Sep 15; doi: 10.1097/CRD.0000000000000419. Epub 2021 Sep 15. PMID: 34560710.
Copy Download .nbib Format: NLM
Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.

Experimental and clinical cardiology

Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, Nishiyama A, Takeda N.
PMID: 18650977
Exp Clin Cardiol. 2007;12(1):33-6.

BACKGROUND: Cardiac hypertrophy and failure are major complications of hypertension.OBJECTIVES: The beneficial effect of treatment with antihypertensive drugs on serum levels of brain natriuretic peptide (BNP) was examined in patients with essential hypertension.METHODS: Antihypertensive drugs were administered to 88...

Cite
Shikata C, Sekikawa T, Kimura N, et al. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardiol. 2007;12(1):33-6
Shikata, C., Sekikawa, T., Kimura, N., Kojima, A., Seki, S., Oka, H., Nishiyama, A., & Takeda, N. (2007). Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Experimental and clinical cardiology, 12(1), 33-6.
Shikata, Chihiro, et al. "Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension." Experimental and clinical cardiology vol. 12,1 (2007): 33-6.
Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, Nishiyama A, Takeda N. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardiol. 2007;12(1):33-6. PMID: 18650977; PMCID: PMC2359624.
Copy Download .nbib Format: NLM
Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.

Clinical and translational science

Hirvensalo P, Tornio A, Tapaninen T, Paile-Hyvärinen M, Neuvonen M, Backman JT, Niemi M.
PMID: 34585840
Clin Transl Sci. 2021 Sep 29; doi: 10.1111/cts.13159. Epub 2021 Sep 29.

The aim of this study was to search for associations of genetic variants with celiprolol pharmacokinetics in a large set of pharmacokinetic genes, and, more specifically, in a set of previously identified candidate genes ABCB1, SLCO1A2, and SLCO2B1. To...

Cite
Hirvensalo P, Tornio A, Tapaninen T, et al. Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clin Transl Sci. 2021;doi: 10.1111/cts.13159.
Hirvensalo, P., Tornio, A., Tapaninen, T., Paile-Hyvärinen, M., Neuvonen, M., Backman, J. T., & Niemi, M. (2021). Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clinical and translational science, . https://doi.org/10.1111/cts.13159
Hirvensalo, Päivi, et al. "Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics." Clinical and translational science vol. (2021). doi: https://doi.org/10.1111/cts.13159
Hirvensalo P, Tornio A, Tapaninen T, Paile-Hyvärinen M, Neuvonen M, Backman JT, Niemi M. Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clin Transl Sci. 2021 Sep 29; doi: 10.1111/cts.13159. Epub 2021 Sep 29. PMID: 34585840.
Copy Download .nbib Format: NLM
[Enatiomeric separation of beta-blocking agents and analogs].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Yu LS, Yao TW, Wang XJ, Zeng S.
PMID: 12601855
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(6):414-418. doi: 10.3785/j.issn.1008-9292.2002.06.004.

OBJECTIVE: To evaluate enantiomeric separation methods for beta-blocking agents and analogs. METHODS: Enantiomeric separation of racemates of 11 beta-blocking agents and their analogs was performed using chiral stationary phases and 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl isothiocyanate (GITC). RESULTS: These beta -blocker racemates were...

Cite
Yu LS, Yao TW, Wang XJ, et al. [Enatiomeric separation of beta-blocking agents and analogs]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002;31(6):414-418doi: 10.3785/j.issn.1008-9292.2002.06.004.
Yu, L. S., Yao, T. W., Wang, X. J., & Zeng, S. (2002). [Enatiomeric separation of beta-blocking agents and analogs]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 31(6), 414-418. https://doi.org/10.3785/j.issn.1008-9292.2002.06.004
Yu, Lu-Shan, et al. "[Enatiomeric separation of beta-blocking agents and analogs]." Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences vol. 31,6 (2002): 414-418. doi: https://doi.org/10.3785/j.issn.1008-9292.2002.06.004
Yu LS, Yao TW, Wang XJ, Zeng S. [Enatiomeric separation of beta-blocking agents and analogs]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2002 Aug;31(6):414-418. doi: 10.3785/j.issn.1008-9292.2002.06.004. Chinese. PMID: 12601855.
Copy Download .nbib Format: NLM
Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods.

Talanta

Ali I, Gupta VK, Singh P, Pant HV.
PMID: 18970411
Talanta. 2006 Jan 15;68(3):928-31. doi: 10.1016/j.talanta.2005.06.027. Epub 2005 Jul 22.

Domperidone is a dopamine D(2) receptor antagonist, which has been used as antiemetic agent in human beings. It has been found in wastewater released by some pharmaceutical industries leading to the contamination of surface and ground water. Therefore, a...

Cite
Ali I, Gupta VK, Singh P, et al. Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2005;68(3):928-31doi: 10.1016/j.talanta.2005.06.027.
Ali, I., Gupta, V. K., Singh, P., & Pant, H. V. (2006). Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta, 68(3), 928-31. https://doi.org/10.1016/j.talanta.2005.06.027
Ali, Imran, et al. "Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods." Talanta vol. 68,3 (2006): 928-31. doi: https://doi.org/10.1016/j.talanta.2005.06.027
Ali I, Gupta VK, Singh P, Pant HV. Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. doi: 10.1016/j.talanta.2005.06.027. Epub 2005 Jul 22. PMID: 18970411.
Copy Download .nbib Format: NLM
Celiprolol: A Unique Selective Adrenoceptor Modulator.

Cardiology in review

Nawarskas JJ, Cheng-Lai A, Frishman WH.
PMID: 28742547
Cardiol Rev. 2017 Sep/Oct;25(5):247-253. doi: 10.1097/CRD.0000000000000159.

Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal...

Cite
Nawarskas JJ, Cheng-Lai A, Frishman WH. Celiprolol: A Unique Selective Adrenoceptor Modulator. Cardiol Rev. 2017;25(5):247-253doi: 10.1097/CRD.0000000000000159.
Nawarskas, J. J., Cheng-Lai, A., & Frishman, W. H. (2017). Celiprolol: A Unique Selective Adrenoceptor Modulator. Cardiology in review, 25(5), 247-253. https://doi.org/10.1097/CRD.0000000000000159
Nawarskas, James J, et al. "Celiprolol: A Unique Selective Adrenoceptor Modulator." Cardiology in review vol. 25,5 (2017): 247-253. doi: https://doi.org/10.1097/CRD.0000000000000159
Nawarskas JJ, Cheng-Lai A, Frishman WH. Celiprolol: A Unique Selective Adrenoceptor Modulator. Cardiol Rev. 2017 Sep/Oct;25(5):247-253. doi: 10.1097/CRD.0000000000000159. PMID: 28742547; PMCID: PMC5549637.
Copy Download .nbib Format: NLM
The Antioxidant Therapy: New Insights in the Treatment of Hypertension.

Frontiers in physiology

Sorriento D, De Luca N, Trimarco B, Iaccarino G.
PMID: 29618986
Front Physiol. 2018 Mar 21;9:258. doi: 10.3389/fphys.2018.00258. eCollection 2018.

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) play a key role in the regulation of the physiological and pathological signaling within the vasculature. In physiological conditions, a delicate balance between oxidants and antioxidants protects cells from the...

Cite
Sorriento D, De Luca N, Trimarco B, et al. The Antioxidant Therapy: New Insights in the Treatment of Hypertension. Front Physiol. 2018;9:258doi: 10.3389/fphys.2018.00258.
Sorriento, D., De Luca, N., Trimarco, B., & Iaccarino, G. (2018). The Antioxidant Therapy: New Insights in the Treatment of Hypertension. Frontiers in physiology, 9258. https://doi.org/10.3389/fphys.2018.00258
Sorriento, Daniela, et al. "The Antioxidant Therapy: New Insights in the Treatment of Hypertension." Frontiers in physiology vol. 9 (2018): 258. doi: https://doi.org/10.3389/fphys.2018.00258
Sorriento D, De Luca N, Trimarco B, Iaccarino G. The Antioxidant Therapy: New Insights in the Treatment of Hypertension. Front Physiol. 2018 Mar 21;9:258. doi: 10.3389/fphys.2018.00258. eCollection 2018. PMID: 29618986; PMCID: PMC5871811.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries